PSI-6130

From Self-sufficiency
Jump to: navigation, search
PSI-6130
File:PSI-6130.png
Systematic (IUPAC) name
4-Amino-1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1H)-one
Identifiers
CAS Number 817204-33-4
ATC code none
Chemical data
Formula C10H14FN3O4
Molar mass 259.23 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

PSI-6130 is an experimental treatment for hepatitis C. PSI-6130 is a member of a class of antiviral drugs known as nucleoside polymerase inhibitors that was created by chemist Jeremy L. Clark.[1] Specifically, PSI-6130 inhibits the hepatitis C virus NS5B RNA dependant RNA polymerase.[2]

PSI-6130 is currently being developed by Hoffmann–La Roche as a 3',5'-diisobutyrl ester prodrug, R7128.[3] R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1.[4][unreliable source?]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  1. Clark, J., et. al. (2005). "Design, synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'C-methylcytidine, a potent inhibitor of hepatitis C virus replication". Journal of Medicinal Chemistry. 48 (17): 5504. doi:10.1021/jm0502788. 
  2. Lieven J Stuyver, Tamara R McBrayer, Phillip M Tharnish, Jeremy Clark, Laurent Hollecker, et. al. (2006). "Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication". Antiviral Chemistry & Chemotherapy. 17 (2): 79–87. 
  3. Cole, P.; Castaner, R.; Bolos, J. (2009). "R-7128: RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection". Drugs of the Future. 34 (4): 282–290. 
  4. "INFORM-1 (R7227 and R7128) study".